Medivir Expands Share Capital After Directed Issue to Carl Bennet AB

An update from Medivir AB ( (SE:MVIR) ) is now available.

Medivir AB has expanded its share capital following a directed issue of 90,000,000 new ordinary shares to Carl Bennet AB in February 2026, increasing the total number of shares to 541,121,383 and total votes to 538,916,236.3. The new capital structure, disclosed in line with Swedish financial market regulations, strengthens Medivir’s financial base as it advances its late-stage oncology and rare disease programs, with implications for existing shareholders’ ownership and voting dilution but potentially enhanced funding for its key pipeline assets.

As of the last trading day of February, Medivir’s share mix comprises 538,671,220 ordinary shares and 2,450,163 class C-shares, where ordinary shares carry one vote and class C-shares carry one-tenth of a vote. This detailed breakdown of equity and voting rights clarifies the company’s governance framework for investors and underscores the strategic role of the new directed issue in supporting Medivir’s growth ambitions within the small-cap biotech segment on Nasdaq Stockholm.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish biopharmaceutical company that develops innovative therapies for diseases with high unmet medical need. Its lead drug candidates include fostrox, a precision chemotherapy for liver cancer, and MIV-711 for Osteogenesis Imperfecta, both viewed as potential blockbuster treatments in collaboration-driven development programs.

Average Trading Volume: 5,711,742

Technical Sentiment Signal: Sell

Current Market Cap: SEK669M

For an in-depth examination of MVIR stock, go to TipRanks’ Overview page.